The New Out-Licensing Start-Ups: Securing Product Supply
This article was originally published in Start Up
Executive Summary
A new crop of companies deals head-on with Big Pharma's biggest out-licensing problems--transaction cost and the "embarrassment factor." Solving both involves strategies to make the extra work of out-licensing worthwhile for their large partners. In particular, after years of resisting the idea, they're now allowing their Big Pharma partners the right to buy back the compounds, usually after clinical proof of concept.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept
The founders of Lilly's radical Chorus experiment have left the mother ship to do the extraordinarily fast and inexpensive proof-of-concept development that have made Chorus one of the most interesting models in the industry. The two new entrepreneurs, backed by Versant, hope that their new company, Flexion, will be able to preferentially sign deals for the shelved molecules that a host of in-licensing start-ups have also been seeking.